Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): A randomised controlled trial

British Journal of General Practice

Volumn 61, Issue 593, 2011, Pages

  Wright, Nat M J ^a   Sheard, Laura ^b   Adams, Clive E ^c   Rushforth, Bruno J ^d   Harrison, Wendy ^e   Bound, Nicole ^f   Hart, Roger ^f   Tompkins, Charlotte N E ^a  

^a NATIONAL HEALTH SERVICE   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f NONE

Author keywords

Opiate substitution treatment; Prison; Randomised controlled trial

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; ILLICIT DRUG; METHADONE;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONFIDENCE INTERVAL; DRUG DETOXIFICATION; DRUG WITHDRAWAL; HEALTH CARE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PRISON; RANDOMIZED CONTROLLED TRIAL; RISK; SELF REPORT; UNITED KINGDOM; URINALYSIS;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ADULT; AGED; BUPRENORPHINE; HUMANS; METHADONE; MIDDLE AGED; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRISONERS; YOUNG ADULT;

EID: 83355163485     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp11X613106     Document Type: Article

References (36)

1. National Offender Management Service. Strategy for the management and treatment of problematic drug users within the correctional facilities. London: National Offender Management Service, 2005.
2. Department of Health and the Devolved Administrations. Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health and the Devolved Administrations, 2007.
3. Department of Health. Clinical management of drug dependence in the adult prison setting. London: Department of Health, 2006.
4. Mattick R, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; (2): CD002207.
5. Stallwitz A, Stover H. The impact of substitution treatment in prisons - a literature review. Int J Drug Policy 2007; 18(6): 464-474. (Pubitemid 350193222)
6. Dolan K, Shearer J, White B, Wodak A. A randomised controlled trial of methadone maintenance treatment in NSW prisons. Technical Report 155. Sydney, Australia: National Drug and Alcohol Research Centre, 2002.
7. Kinlock T, Gordon M, Schwartz P, et al. A randomized clinical trial of methadone maintenance for prisoners: results at 1 month post release. Drug Alcohol Depend 2007; 91(2-3): 220.
8. Gordon M, Kinlock T, Schwartz P, O'Grady K. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post release Addiction 2008; 103(8): 1333-1342. (Pubitemid 352009044)
9. Tompkins C, Neale J, Sheard L, Wright N. Experiences of prison among injecting drug users in England: a qualitative study. Int J Prison Health 2007; 3(3): 189-203. (Pubitemid 47124037)
10. Wright N, Oldham N, Jones L. Exploring the relationship between homelessness and risk factors for heroin related death - a qualitative study. Drug Alcohol Rev 2005; 24(3): 245-251. (Pubitemid 41451935)
11. National Treatment Agency for Substance Misuse. Models of care for adult drug misusers. London: Department of Health, 2002.
12. Department of Health. Drug misuse and dependence: guidelines on clinical management. London: Stationery Office, 1999.
13. Hek G. Unlocking potential: challenges for primary health care researchers in the prison setting. Prim Health Care Res Dev 2006; 7: 91-94.
14. Royal College of Psychiatrists and Royal College of General Practitioners. Roles and responsibilities of doctors in the provision of treatment for drug and alcohol misusers. Council report CR131. London: Royal College of Psychiatrists, 2005.
15. GPs take growing role in drug misuse fight. Pulse 18 July 2008. http://www.pulsetoday.co.uk/newsarticle-content/-/article-display-list/10984435/ gps-take-growing-role-in-drug-misuse-fight (accessed 3 Oct 2011).
16. Strang J, Sheridan J, Hunt C, et al. The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales. Br J Gen Pract 2005; 55(515): 444-451. (Pubitemid 40790098)
17. Matheson C, Porteous T, van Teijlingen E, Bond C. Management of drug misuse: an 8-year follow-up survey of Scottish GPs. Br J Gen Pract 2010; 60(576): 517-520.
18. de Wet C, Reed L, Bearn J. The rise of buprenorphine prescribing in England: analysis of NHS regional data 2001-03. Addiction 2005; 100(4): 495-499. (Pubitemid 40529842)
19. Piper, M. Health promotion and health education in the prison setting [oral presentation]. First International Conference on Prison Healthcare. London, September 2004.
20. Bickel W, Stitzer M, Bigelow G, et al. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988; 43(1): 72-78. (Pubitemid 18052024)
21. Cameron D, Allen D, Galway K. A pilot study of the effectiveness of buprenorphine and methadone as detoxification agents when choice is given to the consumer. J Subst Use 2001; 6: 101-109. (Pubitemid 32737443)
22. Ebner R, Schreiber W, Zierer C. Buprenorphine or methadone for detoxification of young opioid addicts? Psychiatr Prax 2004; 31(Suppl 1): 108-110.
23. Petitjean S, von Bardeleben U, Weber M, Ladewig D. Buprenorphine versus methadone in opiate detoxification: preliminary results. Drug Alcohol Depend 2002; 66(Suppl 1): 138.
24. Seifert J, Metzner C, Paetzold W, et al. Detoxification of opiate addicts with multiple drug abuse: A comparison of buprenorphine vs methadone. Pharmacopsychiatry 2002; 35(5): 159-164.
25. Umbricht A, Hoover D, Tucker M, et al. Opioid detoxification with buprenorphine, clonidine or methadone in hospitalized heroin-dependent patients with HIV infection. Drug Alcohol Depend 2003; 69(3): 263-272. (Pubitemid 36293938)
26. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2009; (3): CD002025.
27. Yaphe J, Edman R, Knishkowy B, Herman J. The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam Pract 2001; 18(6): 565-568. (Pubitemid 34026576)
28. Wood L, Egger M, Gluud L, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008; 336(7644): 601-605. (Pubitemid 351439518)
29. Sheard L, Tompkins C, Wright N, Adams C. Non-commercial clinical trials of a medicinal product: Can they survive the current research approvals process in the United Kingdom? J Med Ethics 2006; 32(7): 430-434. (Pubitemid 44070013)
30. Sheard L, Wright N, Adams C, et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. Trials 2009; 10: 53.
31. National Institute for Health and Clinical Excellence. Drug misuse: opioid detoxification. London: National Institute for Health and Clinical Excellence, 2007. http://guidance.nice.org.uk/CG52/Guidance/pdf/English (accessed 4 Oct 2011).
32. Tompkins C, Neale J, Sheard L, Wright N. Experiences of prison among injecting drug users in England: a qualitative study. Int J Prison Health 2007; 3(3): 189-203. (Pubitemid 47124037)
33. Wright N, Marteau D, Palmer J. The offender and drug treatment: making it work across prisons and wider secure environments. Leeds: Wrighthealth Publishing, 2010.
34. Lobmaier P, Kunoe K, Waal H. Treatment research in prison: problems and solutions in a randomized trial. Addict Res Theory 2010; 18(1): 1-13.
35. Howells C, Allen S, Gupta J, et al. Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug Alcohol Depend 2002; 67(2): 169-176. (Pubitemid 34722404)
36. Sheard L, Wright N, El-Sayeh H, et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) Prisons Project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification. Subst Abuse Treat Prev Policy 2009; 4: 1.